Q-omics provides the consensus-scored AZIN1 profile across patient tissues and cancer cell-line models. AZIN1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, AZIN1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, AZIN1 RNA expression shows 19,843 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where AZIN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AZIN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AZIN1 survival associations across molecular data types. AZIN1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AZIN1 RNA expression–survival associations across cancer types. High AZIN1 expression shows unfavorable associations in KIRP, UVM, MESO, CESC and HNSC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for AZIN1 RNA expression.
This table summarizes AZIN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for AZIN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AZIN1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, COAD and READ. The HNSC box plot shows higher AZIN1 RNA expression in tumor versus normal tissue (log2 FC = +0.864, t-test p < 0.001).
This table shows molecular features associated with AZIN1 in patient tissues and cancer cell lines. In patient samples, AZIN1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AZIN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
